The HERPUD1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population with targeted disruption of the human HERPUD1 gene, serving as a loss-of-function model in a colorectal adenocarcinoma host. This heterogeneous cell pool avoids clonal artifacts and is ideal for investigating HERPUD1’s role in endoplasmic reticulum (ER) stress and ER-associated degradation (ERAD). The polyclonal format preserves the biological characteristics of the parental HT29 line while enabling robust functional studies.
HT29 cells originate from a primary colorectal adenocarcinoma of a 44-year-old female, displaying an epithelial phenotype with intestinal differentiation potential. As a widely used model for colon cancer, these cells retain transformed features such as dysregulated proliferation and stress responses, making them particularly suitable for probing the intersection of oncogenic signaling and protein quality control mechanisms.
HERPUD1 is an ER stress-responsive scaffold essential for ERAD. Transcriptionally induced by UPR sensors (IRE1, PERK, ATF6) and stimuli like tunicamycin or thapsigargin, HERPUD1 coordinates the degradation of misfolded ER proteins. It recruits Derlin-1, VIMP, and p97/VCP to extract substrates for ubiquitin-proteasome degradation, while interacting with HRD1, Derlin-2, and proteasome subunits. This process suppresses CHOP expression and inhibits caspase-3/7 activation, thereby attenuating apoptosis. HERPUD1 thus acts as a critical node linking ER stress sensing to cell survival decisions.
In HT29 colorectal cancer cells, HERPUD1 likely promotes tumor cell survival by countering ER stress-induced apoptosis, a common challenge in the tumor microenvironment. Knocking out HERPUD1 sensitizes cells to ER stressors and may uncover vulnerabilities in ERAD that contribute to chemoresistance. This model thus provides a physiologically relevant system to study how colorectal malignancies subvert protein quality control for therapeutic resistance.
Typical applications include Western blotting for UPR and ERAD proteins, RT-qPCR analysis of ER stress genes, and stress induction assays with tunicamycin or thapsigargin. Users can perform apoptosis assays (Annexin V), co-immunoprecipitation to capture HERPUD1 complexes, flow cytometry for cell cycle, and drug sensitivity testing to evaluate chemoresistance pathways. For further details, please contact Ascent Research.
